JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 214 filers reported holding JUNO THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is 0.99 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $0 | – | 0 | – | 0.00% | – |
| Q1 2021 | $0 | – | 0 | – | 0.00% | – |
| Q4 2020 | $0 | – | 0 | – | 0.00% | – |
| Q3 2020 | $0 | – | 0 | – | 0.00% | – |
| Q2 2020 | $0 | – | 0 | – | 0.00% | – |
| Q1 2020 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| Q1 2018 | $159,000 | 0.0% | 3,484 | 0.0% | 0.01% | 0.0% |
| Q4 2017 | $159,000 | -4.2% | 3,484 | -5.7% | 0.01% | 0.0% |
| Q3 2017 | $166,000 | +58.1% | 3,695 | +5.0% | 0.01% | +75.0% |
| Q2 2017 | $105,000 | +28.0% | 3,519 | -4.2% | 0.00% | 0.0% |
| Q1 2017 | $82,000 | +134.3% | 3,674 | +97.2% | 0.00% | +100.0% |
| Q4 2016 | $35,000 | -80.7% | 1,863 | -69.1% | 0.00% | -77.8% |
| Q3 2016 | $181,000 | -45.3% | 6,028 | -29.9% | 0.01% | -50.0% |
| Q2 2016 | $331,000 | +190.4% | 8,599 | +230.2% | 0.02% | +125.0% |
| Q4 2015 | $114,000 | – | 2,604 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 1,864,174 | $85,211,000 | 94.86% |
| Crestline Management, LP | 7,631,631 | $348,841,000 | 35.74% |
| Omega Fund Management, LLC | 753,564 | $34,445,000 | 24.90% |
| DDD Partners, LLC | 191,458 | $8,752,000 | 3.40% |
| SIB LLC | 100,000 | $4,571,000 | 3.28% |
| PECONIC PARTNERS LLC | 433,587 | $19,819,000 | 2.85% |
| Cormorant Asset Management, LP | 550,000 | $25,141,000 | 2.63% |
| ARK Investment Management | 682,495 | $31,197,000 | 2.48% |
| BB BIOTECH AG | 1,925,000 | $87,992,000 | 2.48% |
| Clarius Group, LLC | 120,988 | $5,530,000 | 2.47% |